In The Middle Of The Ozempic Gold Rush Habitual Refused the “Easy” Revenue: We Find Out Why

GLP-1 medications like Ozempic and Mounjaro have changed the world, but they aren't a silver bullet.

Napala Pratini, co-founder of Habitual, joins David to discuss the “hard stuff” behind the hype: behavior change, side effects, and the ethics of digital health. She reveals why her company turned down the chance to just “stack drugs high and sell them cheap” and opens up about the isolation of the “toxic founder cult.”

WhatsApp us on +447392087344

Want to read the latest from David, his Substack (diving into ‘Tech Talks’ and more) is here.

Tech Talks is powered by Nash Squared, the leading global provider of technology and talent solutions. Click here to learn more about our services.

The music on Tech Talks is created by London artist Lemzi.